Single-dose intravenous ketamine or intramuscular naltrexone for highutilization inpatients with alcohol use disorder: pilot trial feasibility and readmission rates


PRESENTER: Zachary Haave

BACKGROUND

Alcohol use disorder (AUD) impacts 15 million Americans leading to 5 million annual emergency department (ED) visits and 2 million admissions. AUD poses a burden on the healthcare system, yet hospitalization provides a prime opportunity to intervene. We set out to assess two pharmacologic interventions at reducing ED visits and readmissions along with characterizing this population.

METHODS

- 1. Adult hospitalized patients with severe AUD recruited into one of three trial groups: extended-release naltrexone injection, intravenous ketamine infusion, or enhanced linkage alone
- 2. Demographics, adverse childhood experiences (ACE), Timeline Follow Back drinking history (TLFB), and depressive symptoms (PHQ-9), are recorded at baseline
- 3. Initiate treatment based on group before discharge
- 4. 30-day chart review for ED visits and hospital admissions
- 5. Data analysis for correlations and significance performed (Pearson r correlations, Means, T- test)



RESULTS

- Ketamine vs LA Re-admit RR 0.37, **p*=0.17
- Naltrexone vs LA Re-admit RR 0.52, **p*=0.27


Demographics:

- Race: 63.6% non-Hispanic, 56.8% white/Caucasian
- 79.6% male
- 38.6% without stable housing

Clinical Characteristics:

- Mean Past year ED visits: 10.9
- Mean Past year Hospital Admissions: 3.2
- Mean Daily Drinks: 12.14





Participants with AUD who received one dose of V ketamine or IM naltrexone predischarge had lower* 30-day hospital re-admission risks and ED visits than controls. *not statistically significant

Discussion

- housed

Conclusion

Future Directions

- Larger scale

Contributors:

Zach Haave, BS [b] Dale Terasaki, MD MPH [a,b] Ryan Loh, PhD [a] Anastasia Cornell, MPH [c] Christian Thurstone, MD [a,b]

- Health

er for Behavioral Health Statistics and Quality, "2019 National Survey on Drug Use and Health. Table 5.4A – Alcohol Use Disorder in Past sons Aged 12 or Older, by Age Group and Demographic Characteristics: Numbers in Thousands, 2018 and 2019." Accessed: Sep. 11, 2021 n Alcohol-Related Emergency Department Visits in the United States: Results from the Nationwide Emergency Department es., vol. 42, no. 2, pp. 352–359, 2018 al., "A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam

rial." Am. J. Psychiatry, p. appiaip201919070684, Dec. 2019 Stable I Briefly Chronie Unknov Advanc Jnknov Cardio Electrol Physica

 Hospital administration feasible • Acceptable treatment by patients • Only known study using ketamine for AUD • Linkage arm with higher baseline care utilization and less

Ketamine arm with lower baseline drinking • Limitations: underpowered, no blinding

Both treatments show promise in combating AUD • Hospitalization treatment is opportune and feasible • More research needed for these intriguing new therapies

Ketamine dose could be optimized • Include oral naltrexone



Denver Health & Hospital Authority, Dept of Behavioral

University of Colorado School of Medicine Rocky Mountain Poison & Drug Safety

No financial disclosures for any authors.

	Arm 1 KET	Arm 2 NTX	Arm 3 LA	All Arms
n od)	n=13	n=14	n=17	N=44
n, sd) ı (%)	43.92 (11.48)	44.93 (12.52)	46.17 (9.53)	45.11 (10.90)
e	4 (30.8%)	3 (21.4%)	2 (11.8%)	9 (20.5%)
	9 (69.2%)	11 (78.6%)	15 (88.2%)	35 (79.6%)
inary	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Response	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
% of column)				
Caucasian	9 (69.2%)	4 (28.6%)	12 (70.6%)	25 (56.8%)
African-American	0 (0.0%)	2 (14.3%)	1 (5.9%)	3 (6.8%)
Pacific-Islander can Indian/Alaska-	0 (0.0%) 1 (7.7%)	0 (0.0%) 4 (28.6%)	0 (0.0%) 2 (11.8%)	0 (0.0%) 7 (15.9%)
an mulan/Alaska-	1 (7.776)	4 (20.070)	2 (11.070)	7 (13.976)
е	1 (7.7%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
wn / Other	2 (15.4%)	4 (28.6%)	2 (11.8%)	8 (18.2%)
n (% of column)		()	_ (,	
ispanic/Latinx	6 (61.5%)	8 (57.1%)	12 (70.6%)	28 (63.6%)
nic/Latinx	4 (30.8%)	6 (42.9%)	5 (29.4%)	15 (34.1%)
wn / Other	1 (7.7%)	0 (0.0%)	0 (0.0%)	1 (2.3%)
Status, n (% of				
housing	0 (60.20/)	10 (71 40/)	Q (17 10/)	27 (61.4%)
housing homeless	9 (69.2%) 0 (0.0%)	10 (71.4%) 1 (7.1%)	8 (47.1%) 4 (23.5%)	5 (11.4%)
cally homeless	4 (30.8%)	1 (7.1%)	4 (23.5%)	9 (20.5%)
wn / Other	0 (0.0%)	2 (14.3%)	1 (5.9%)	3 (6.8%)
ducation		()	(*****)	- ()
d, n (% of column)				
h school	1 (7.7%)	2 (14.3%)	2 (11.8%)	5 (11.4%)
chool / GED	6 (46.2%)	9 (64.3%)	9 (64.3%)	24 (54.6%)
onal	2 (15.4%)	1 (7.1%)	1 (5.9%)	4 (9.1%)
e degree	2 (15.4%)	1 (7.1%)	4 (23.5%)	7 (15.9%)
ced degree	2 (15.4%)	0 (0.0)	1 (5.9%)	3 (6.8%)
wn / Other past care	0 (0.00%)	1 (7.1%)	0 (0.0%)	1 (2.3%)
its (mean, sd)	8.46 (7.78)	9.64 (7.62)	13.82 (8.76)	10.91 (8.29)
admits (mean, sd)	2.77 (2.59)	2.86 (2.80)	3.88 (5.33)	3.23 (3.88)
behavioral /	(/			- ()
gical				
ristics, n (%) unless				
l daily drinks (mean,	9.15 (7.04)	14.68 (11.52)	12.13 (9.86)	12.0 (9.69)
(mean, sd)	14.08 (7.30)	13.50 (5.71)	13.18 (6.42)	13.55 (6.34)
core (mean, sd)	3.85 (2.34)	4.41 (3.07)	4.21 (2.65)	4.18 (2.65)
SD" in chart	1 (7.7%)	3 (21.4%)	1 (5.9%)	5 (11.4%)
oolar" in chart hizoaffective" or	1 (7.7%) 0 (0.0%)	3 (21.4%) 0 (0.0%)	2 (11.8%) 0 (0.0%)	6 (13.6%) 0 (0.0%)
ophrenia" in chart	0 (0.078)	0 (0.078)	0 (0.078)	0 (0.078)
nary admission				
s, n (%)				
halopathy /	8 (61.5%)	6 (42.9%)	11 (64.7%)	25 (56.8)
ation / Withdrawal		. ,	· · · · ·	. ,
on / Sepsis	0 (0.0%)	1 (7.1%)	1 (5.9%)	2 (4.5%)
intestinal	2 (15.4%)	2 (14.3%)	1 (5.9%)	5 (11.3%)
pulmonary	2 (15.4%)	3 (21.4%)	2 (11.8%)	7 (15.9%)
olytes / renal	1 (7.7%)	2 (14.3%)	2 (11.8%)	5 (11.3%)
al injury	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
atric	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)